S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
S&P 500   4,267.52 (-0.38%)
DOW   33,665.02 (+0.27%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:BNR

Burning Rock Biotech (BNR) Stock Forecast, Price & News

$2.23
-0.02 (-0.89%)
(As of 04:26 PM ET)
Compare
Today's Range
$2.00
$2.33
50-Day Range
$2.25
$76.54
52-Week Range
$1.70
$4.24
Volume
68,236 shs
Average Volume
107,556 shs
Market Capitalization
$234.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$86.61

Burning Rock Biotech MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
3,836.9% Upside
$86.61 Price Target
Short Interest
Healthy
0.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.69) to ($0.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Business Services Sector

288th out of 330 stocks

Medical Laboratories Industry

21st out of 22 stocks


BNR stock logo

About Burning Rock Biotech (NASDAQ:BNR) Stock

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.

Receive BNR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Burning Rock Biotech and its competitors with MarketBeat's FREE daily newsletter.

BNR Stock News Headlines

Q1 2023 Burning Rock Biotech Ltd Earnings Call
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Burning Rock Publishes 2022 Annual Report on Form 20-F
Earnings Preview: Burning Rock Biotech
Burning Rock Biotech earnings preview: what Wall Street is expecting
BNR Burning Rock Biotech Limited
Burning Rock provides an update on 2022 revenue guidance
See More Headlines

BNR Price History

BNR Company Calendar

Last Earnings
3/28/2023
Today
6/07/2023
Next Earnings (Estimated)
8/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:BNR
Fax
N/A
Employees
1,138
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$86.61
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$76.00
Forecasted Upside/Downside
+3,665.7%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-140,820,000.00
Net Margins
-157.30%
Pretax Margin
-152.71%

Debt

Sales & Book Value

Annual Sales
$81.66 million
Book Value
$1.60 per share

Miscellaneous

Free Float
73,316,000
Market Cap
$241.94 million
Optionable
Not Optionable
Beta
0.18

Key Executives

  • Dr. Shaokun Chuai (Age 44)
    Chief Scientific Officer & Director
  • Mr. Yusheng Han (Age 44)
    Founder, Chairman & CEO
  • Mr. Jinxiang Li (Age 38)
    CFO, Compliance Officer & Director
  • Dr. Zhihong Zhang (Age 47)
    Chief Technology Officer
  • Mr. Hao Liu (Age 49)
    Sr. Advisor













BNR Stock - Frequently Asked Questions

What is Burning Rock Biotech's stock price forecast for 2023?

0 analysts have issued twelve-month price objectives for Burning Rock Biotech's stock. Their BNR share price forecasts range from $76.00 to $100.00. On average, they expect the company's stock price to reach $86.61 in the next year. This suggests a possible upside of 3,665.7% from the stock's current price.
View analysts price targets for BNR
or view top-rated stocks among Wall Street analysts.

How have BNR shares performed in 2023?

Burning Rock Biotech's stock was trading at $59.72 at the beginning of 2023. Since then, BNR shares have decreased by 96.1% and is now trading at $2.30.
View the best growth stocks for 2023 here
.

Are investors shorting Burning Rock Biotech?

Burning Rock Biotech saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 608,200 shares, a drop of 17.4% from the April 30th total of 736,000 shares. Based on an average daily trading volume, of 74,400 shares, the short-interest ratio is currently 8.2 days. Approximately 0.7% of the company's shares are short sold.
View Burning Rock Biotech's Short Interest
.

When is Burning Rock Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 30th 2023.
View our BNR earnings forecast
.

How were Burning Rock Biotech's earnings last quarter?

Burning Rock Biotech Limited (NASDAQ:BNR) released its earnings results on Tuesday, March, 28th. The company reported ($0.31) earnings per share (EPS) for the quarter. The firm had revenue of $20.62 million for the quarter, compared to analyst estimates of $15.60 million. Burning Rock Biotech had a negative trailing twelve-month return on equity of 72.57% and a negative net margin of 157.30%.

What ETFs hold Burning Rock Biotech's stock?

ETFs with the largest weight of Burning Rock Biotech (NASDAQ:BNR) stock in their portfolio include Loncar China Biopharma ETF (CHNA), Invesco Golden Dragon China ETF (PGJ),

What guidance has Burning Rock Biotech issued on next quarter's earnings?

Burning Rock Biotech issued an update on its FY 2023 earnings guidance on Tuesday, May, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $97.99 million-$97.99 million, compared to the consensus revenue estimate of $95.89 million.

What other stocks do shareholders of Burning Rock Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Burning Rock Biotech investors own include Tiziana Life Sciences (TLSA), Teck Resources (TECK), Herman Miller (MLHR) and Immunic (IMUX).

When did Burning Rock Biotech IPO?

(BNR) raised $196 million in an initial public offering on Friday, June 12th 2020. The company issued 13,500,000 shares at $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen served as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers.

What is Burning Rock Biotech's stock symbol?

Burning Rock Biotech trades on the NASDAQ under the ticker symbol "BNR."

Who are Burning Rock Biotech's major shareholders?

Burning Rock Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.63%), Nikko Asset Management Americas Inc. (0.62%), Barclays PLC (0.58%), Renaissance Technologies LLC (0.35%), Assenagon Asset Management S.A. (0.26%) and Schonfeld Strategic Advisors LLC (0.19%).

How do I buy shares of Burning Rock Biotech?

Shares of BNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Burning Rock Biotech's stock price today?

One share of BNR stock can currently be purchased for approximately $2.30.

How much money does Burning Rock Biotech make?

Burning Rock Biotech (NASDAQ:BNR) has a market capitalization of $241.94 million and generates $81.66 million in revenue each year. The company earns $-140,820,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

How many employees does Burning Rock Biotech have?

The company employs 1,138 workers across the globe.

How can I contact Burning Rock Biotech?

Burning Rock Biotech's mailing address is 601 BUILDING 3 STANDARD INDUSTRIAL UNIT2, GUANGZHOU F4, 510005. The official website for the company is www.brbiotech.com. The company can be reached via phone at 86-185-0164-1666.

This page (NASDAQ:BNR) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -